Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
2000 2
2001 1
2002 2
2004 2
2005 2
2009 3
2010 4
2011 1
2012 2
2013 2
2015 1
2019 1
2020 1
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
A highly virulent variant of HIV-1 circulating in the Netherlands.
Wymant C, Bezemer D, Blanquart F, Ferretti L, Gall A, Hall M, Golubchik T, Bakker M, Ong SH, Zhao L, Bonsall D, de Cesare M, MacIntyre-Cockett G, Abeler-Dörner L, Albert J, Bannert N, Fellay J, Grabowski MK, Gunsenheimer-Bartmeyer B, Günthard HF, Kivelä P, Kouyos RD, Laeyendecker O, Meyer L, Porter K, Ristola M, van Sighem A, Berkhout B, Kellam P, Cornelissen M, Reiss P, Fraser C; Netherlands ATHENA HIV Observational Cohort†; BEEHIVE Collaboration†. Wymant C, et al. Science. 2022 Feb 4;375(6580):540-545. doi: 10.1126/science.abk1688. Epub 2022 Feb 3. Science. 2022. PMID: 35113714 Free article.
Without treatment, advanced HIV-CD4 cell counts below 350 cells per cubic millimeter, with long-term clinical consequences-is expected to be reached, on average, 9 months after diagnosis for individuals in their thirties with this variant. Age, sex, suspected mode of trans …
Without treatment, advanced HIV-CD4 cell counts below 350 cells per cubic millimeter, with long-term clinical consequences-is expecte …
Cerebrovascular diseases in HIV-infected patients.
Monsuez JJ, Goujon C, Wyplosz B, Couzigou C, Escaut L, Vittecoq D. Monsuez JJ, et al. Among authors: vittecoq d. Curr HIV Res. 2009 Sep;7(5):475-80. doi: 10.2174/157016209789346345. Curr HIV Res. 2009. PMID: 19534663 Review.
This suggests that vascular prevention should be performed on a long-term basis....
This suggests that vascular prevention should be performed on a long-term basis....
Persistent headaches one year after bacterial meningitis: prevalence, determinants and impact on quality of life.
Van RN, Tubiana S, De Broucker T, Cédric J, Roy C, Meyohas MC, Prazuck T, Chirouze C, Hoen B, Duval X, Revest M; COMBAT study group. Van RN, et al. Eur J Clin Microbiol Infect Dis. 2023 Dec;42(12):1459-1467. doi: 10.1007/s10096-023-04673-y. Epub 2023 Oct 23. Eur J Clin Microbiol Infect Dis. 2023. PMID: 37867184
BACKGROUND: Little is known on headaches long-term persistence after bacterial meningitis and on their impact on patients' quality of life. ...
BACKGROUND: Little is known on headaches long-term persistence after bacterial meningitis and on their impact on patients' quality of …
Recurrent subcutaneous infection due to Scopulariopsis brevicaulis in a liver transplant recipient.
Sellier P, Monsuez JJ, Lacroix C, Feray C, Evans J, Minozzi C, Vayre F, Del Giudice P, Feuilhade M, Pinel C, Vittecoq D, Passeron J. Sellier P, et al. Among authors: vittecoq d. Clin Infect Dis. 2000 May;30(5):820-3. doi: 10.1086/313764. Clin Infect Dis. 2000. PMID: 10816153 Review.
We describe a case of recurrent Scopulariopsis brevicaulis subcutaneous infection, which occurred 6 years after the patient underwent liver transplantation. Combined surgery and long-term oral therapy with terbinafine resulted in a favorable outcome, although this is not t …
We describe a case of recurrent Scopulariopsis brevicaulis subcutaneous infection, which occurred 6 years after the patient underwent liver …
Dynamics in HIV-DNA levels over time in HIV controllers.
Avettand-Fenoel V, Bayan T, Gardiennet E, Boufassa F, Lopez P, Lecuroux C, Noel N, Trémeaux P, Monceaux V, Autran B, Meyer L, Saez-Cirion A, Lambotte O, Rouzioux C; CODEX ANRS Cohort Study Group. Avettand-Fenoel V, et al. J Int AIDS Soc. 2019 Jan;22(1):e25221. doi: 10.1002/jia2.25221. J Int AIDS Soc. 2019. PMID: 30629340 Free PMC article.
CONCLUSIONS: These results offer new insights into the mechanisms of long-term control in HIC. In half of HIC, the decrease in HIV-DNA level could be linked to tighter viral control and progressive loss of infected cells. ...
CONCLUSIONS: These results offer new insights into the mechanisms of long-term control in HIC. In half of HIC, the decrease in HIV-DN …
One-Year Sequelae and Quality of Life in Adults with Meningococcal Meningitis: Lessons from the COMBAT Multicentre Prospective Study.
Duval X, Taha MK, Lamaury I, Escaut L, Gueit I, Manchon P, Tubiana S, Hoen B; COMBAT study group. Duval X, et al. Adv Ther. 2022 Jun;39(6):3031-3041. doi: 10.1007/s12325-022-02149-7. Epub 2022 Apr 28. Adv Ther. 2022. PMID: 35484469 Free PMC article.
CONCLUSIONS: Although most patients in our cohort survive meningococcal meningitis, the long-term burden is substantial and therefore it is important to ensure a prolonged follow-up of survivors and to promote preventive strategies, including vaccination. ...
CONCLUSIONS: Although most patients in our cohort survive meningococcal meningitis, the long-term burden is substantial and therefore …
Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial.
Fagard C, Colin C, Charpentier C, Rami A, Jacomet C, Yeni P, Vittecoq D, Katlama C, Molina JM, Descamps D, Chêne G, Yazdanpanah Y; ANRS 139 TRIO Trial Group. Fagard C, et al. Among authors: vittecoq d. J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):489-93. doi: 10.1097/QAI.0b013e31824bb720. J Acquir Immune Defic Syndr. 2012. PMID: 22293546
Persistence of yellow fever vaccine-induced antibodies after solid organ transplantation.
Wyplosz B, Burdet C, François H, Durrbach A, Duclos-Vallée JC, Mamzer-Bruneel MF, Poujol P, Launay O, Samuel D, Vittecoq D, Consigny PH; GEVACCIM. Wyplosz B, et al. Among authors: vittecoq d. Am J Transplant. 2013 Sep;13(9):2458-61. doi: 10.1111/ajt.12338. Epub 2013 Jul 8. Am J Transplant. 2013. PMID: 23834702 Free article.
For the 46 patients with a known or estimated date of vaccination, yellow-fever antibodies were still detectable after a median time of 13 years (range: 2-32 years) post-immunization. Our data suggest there is long-term persistence of antibodies to yellow fever in SOT reci …
For the 46 patients with a known or estimated date of vaccination, yellow-fever antibodies were still detectable after a median time of 13 y …
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.
Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Clotet B, Zhao J, Wan H, Rhodes RR, Strohmaier KM, Barnard RJ, Isaacs RD, Nguyen BY; BENCHMRK Study Teamsa. Steigbigel RT, et al. Clin Infect Dis. 2010 Feb 15;50(4):605-12. doi: 10.1086/650002. Clin Infect Dis. 2010. PMID: 20085491 Free PMC article. Clinical Trial.
29 results